Study,Reason for dropping,Qty,# People,Phase,Arm/Group Title,Radiation,Randomized,Neo,Neo Drug,Neo Drug Dosage,Neo Drug Dosage Unit,Surgery,Concomitant,Concomitant Drug,Concomitant Drug Dosage,Concomitant Drug Dose Unit,IV for Concomitant Drug,Duration of IV for Concomitant Drug,Concomitant Temodal2, Concomitant Temodal Dose,Concomitant Temodal Dose Unit,Adjuvant,Adjuvant TEM,Adjuvant TEM 1 Dosage,Adjuvant TEM 1 dosage unit,Adjuvant TEM 2 Dosage,Adjuvant TEM 2 doage unit,Adjuvant Drug 1,Adjuvant Drug 1 dosage,Adjuvant Drug 1 Dosage Unit,IV for Adjuvant Drug 1,Duration of IV for Adjuvant Drug 1,Adjuvant Drug 2,Adjuvant Drug 2 dosage,Adjuvant Drug 2 Dosage Unit,IV for Adjuvant Drug 2,Duration of IV for Adjuvant Drug 2,SOC,Recurrent,Methylated,Treatment Drug 1,Treatment Drug 1 Dose,Treatment Drug 1 Dose Unit,IV for Treatment Drug 1,Duration of IV for Treatment Drug 1,Oral Injection,Duration of Oral Injection,Treatment Drug 2,Dose for Treatment drug 2,Dosage Unit for Treatment Drug 2,IV for treatment drug 2,Duration of IV for Treatment Drug 2,Universal IV,Overall Survival (months),IV for Adjuvant All Phases
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Protocol Violation,3,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Regular,10,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Withdrawal by Subject,6,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Lost to Follow-Up,1,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Death,102,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Severe protocol deviation,0,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,None,0,122,2,Bevacizumab + Irinotecan,TRUE,TRUE,,,,,,TRUE,Bevacizumab,10,mg/kg,TRUE,1,FALSE,,,TRUE,FALSE,,,,,Bevacizumab,10,mg/kg,TRUE,1,Irinotecan,125,mg/m2,TRUE,1.5,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.64,TRUE
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Protocol Violation,4,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Regular,3,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Withdrawal by Subject,0,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Lost to Follow-Up,1,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Death,51,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,Severe protocol deviation,1,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma,None,0,60,2,Temozolomide,FALSE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.3,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),None,41,131,3,Cediranib,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,30,mg,FALSE,,,,,,,,,FALSE,8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Lost to Follow-up,1,131,3,Cediranib,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,30,mg,FALSE,,,,,,,,,FALSE,8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Death,85,131,3,Cediranib,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,30,mg,FALSE,,,,,,,,,FALSE,8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Withdrawal by Subject,3,131,3,Cediranib,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,30,mg,FALSE,,,,,,,,,FALSE,8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Incorrect enrol/elig crit not fulfilled,1,131,3,Cediranib,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,30,mg,FALSE,,,,,,,,,FALSE,8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),None,46,129,3,Cediranib + Lomustine,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,20,mg,FALSE,,,,Lomustine,110,mg/m2,FALSE,,FALSE,9.4,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Lost to Follow-up,1,129,3,Cediranib + Lomustine,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,20,mg,FALSE,,,,Lomustine,110,mg/m2,FALSE,,FALSE,9.4,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Death,73,129,3,Cediranib + Lomustine,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,20,mg,FALSE,,,,Lomustine,110,mg/m2,FALSE,,FALSE,9.4,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Withdrawal by Subject,4,129,3,Cediranib + Lomustine,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,20,mg,FALSE,,,,Lomustine,110,mg/m2,FALSE,,FALSE,9.4,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Incorrect enrol/elig crit not fulfilled,5,129,3,Cediranib + Lomustine,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cediranib,20,mg,FALSE,,,,Lomustine,110,mg/m2,FALSE,,FALSE,9.4,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),None,28,65,3,Lomustime,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Lomustine,110,mg/m2,FALSE,,,,Placebo Cediranib,20,mg,FALSE,,FALSE,9.8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Lost to Follow-up,0,65,3,Lomustime,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Lomustine,110,mg/m2,FALSE,,,,Placebo Cediranib,20,mg,FALSE,,FALSE,9.8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Death,33,65,3,Lomustime,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Lomustine,110,mg/m2,FALSE,,,,Placebo Cediranib,20,mg,FALSE,,FALSE,9.8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Withdrawal by Subject,3,65,3,Lomustime,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Lomustine,110,mg/m2,FALSE,,,,Placebo Cediranib,20,mg,FALSE,,FALSE,9.8,
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL),Incorrect enrol/elig crit not fulfilled,1,65,3,Lomustime,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Lomustine,110,mg/m2,FALSE,,,,Placebo Cediranib,20,mg,FALSE,,FALSE,9.8,
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor),None,41,41,2,Cilengitide 500 Milligram (mg),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cilengitide,500,mg,TRUE,1,,,,,,,,TRUE,6.54,
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor),None,40,40,2,Cilengitide 2000 Milligram (mg),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Cilengitide,2000,mg,TRUE,1,,,,,,,,TRUE,9.91,
"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)",None,233,272,3,Cilengitide + Temozolomide + Radiotherapy,TRUE,TRUE,,,,,,TRUE,Cilengitide,2000,mg,TRUE,1,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,Cilengitide,2000,mg,TRUE,1,,,,,,TRUE,FALSE,TRUE,,,,,,,,,,,,,TRUE,26.3,TRUE
"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)",Ongoing at cut-off date,39,272,3,Cilengitide + Temozolomide + Radiotherapy,TRUE,TRUE,,,,,,TRUE,Cilengitide,2000,mg,TRUE,1,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,Cilengitide,2000,mg,TRUE,1,,,,,,TRUE,FALSE,TRUE,,,,,,,,,,,,,TRUE,26.3,TRUE
"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)",None,237,273,3,Temozolomide + Radiotherapy,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,TRUE,,,,,,,,,,,,,FALSE,26.3,
"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)",Ongoing at cut-off date,36,273,3,Temozolomide + Radiotherapy,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,175,mg/m2,,,,,,,,,,,,,TRUE,FALSE,TRUE,,,,,,,,,,,,,FALSE,26.3,
"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,46,46,2,Arm 2 - Phase II (Treatment 1),TRUE,TRUE,,,,,,TRUE,Cilengitide,500,mg,TRUE,1,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Cilengitide,500,mg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,,TRUE
"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,48,48,2,Arm 3 - Phase II (Treatment 2),TRUE,TRUE,,,,,,TRUE,Cilengitide,2000,mg,TRUE,1,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Cilengitide,20000,mg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,19.7,TRUE
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Still Receiving Study Treatment,0,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Disease Progression,2,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Adverse Event,1,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Withdrawal by Subject,2,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Death,1,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Non-Permitted Interventions,0,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Study Compliance,0,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Declining Performance Status,0,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,None,0,6,1,"Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Still Receiving Study Treatment,0,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Disease Progression,4,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Adverse Event,1,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Withdrawal by Subject,0,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Death,1,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Non-Permitted Interventions,0,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Study Compliance,0,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Declining Performance Status,0,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,None,0,6,1,"Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,80,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,1,TRUE,,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Still Receiving Study Treatment,1,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Disease Progression,50,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Adverse Event,12,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Withdrawal by Subject,9,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Death,0,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Non-Permitted Interventions,2,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Study Compliance,1,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,Declining Performance Status,1,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,None,0,76,2,"Phase II - (60 mg BKM120, 10mg/kg Bevacizumab)",FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,BKM120,60,mg,FALSE,,,,Bevacizumab,10,mg/kg,TRUE,,TRUE,10.8,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,3,3,1,Dose Level 0- Phase I,TRUE,TRUE,,,,,,TRUE,Dasatinib,100,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,100,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Withdrawal by Subject,0,3,1,Dose Level 0- Phase I,TRUE,TRUE,,,,,,TRUE,Dasatinib,100,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,100,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Withdrawal by Subject,0,3,1,Dose Level 0-A Phase I,TRUE,TRUE,,,,,,TRUE,Dasatinib,100,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,100,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,3,3,1,Dose Level 0-A Phase I,TRUE,TRUE,,,,,,TRUE,Dasatinib,100,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,100,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Withdrawal by Subject,0,7,1,Dose Level 1 Phase I,TRUE,TRUE,,,,,,TRUE,Dasatinib,150,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,150,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,7,7,1,Dose Level 1 Phase I,TRUE,TRUE,,,,,,TRUE,Dasatinib,150,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,150,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Withdrawal by Subject,5,138,2,Group 1 (Phase II) Dasatinib + Radiation + Temozolomide,TRUE,TRUE,,,,,,TRUE,Dasatinib,150,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,150,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,15.6,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,133,138,2,Group 1 (Phase II) Dasatinib + Radiation + Temozolomide,TRUE,TRUE,,,,,,TRUE,Dasatinib,150,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Dasatinib,150,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,15.6,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Withdrawal by Subject,3,66,2,Group 2 (Phase II) Placebo + Radiation + Temozolomide,TRUE,TRUE,,,,,,TRUE,Placebo,150,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Placebo,150,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,19.3,
"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,63,66,2,Group 2 (Phase II) Placebo + Radiation + Temozolomide,TRUE,TRUE,,,,,,TRUE,Placebo,150,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,Placebo,150,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,19.3,
"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Ineligible / No protocol treatment	",1,10,1,Phase I: MGd 4 mg/kg,TRUE,FALSE,,,,,,TRUE,Mgd,4,mg/kg,TRUE,0.5,TRUE,75,mg/m2,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,,
"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Ineligible / No protocol treatment	",1,7,1,Phase I: MGd 5 mg/kg,TRUE,FALSE,,,,,,TRUE,Mgd,5,mg/kg,TRUE,0.5,TRUE,75,mg/m2,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,,
"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Ineligible / No protocol treatment	",13,94,2,Phase II: MGd 5 mg/kg,TRUE,FALSE,,,,,,TRUE,Mgd,5,mg/kg,TRUE,0.5,TRUE,75,mg/m2,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.6,
"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",None,9,10,1,Phase I: MGd 4 mg/kg,TRUE,FALSE,,,,,,TRUE,Mgd,4,mg/kg,TRUE,0.5,TRUE,75,mg/m2,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.6,
"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",None,6,7,1,Phase I: MGd 5 mg/kg,TRUE,FALSE,,,,,,TRUE,Mgd,5,mg/kg,TRUE,0.5,TRUE,75,mg/m2,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.6,
"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",None,81,94,2,Phase II: MGd 5 mg/kg,TRUE,FALSE,,,,,,TRUE,Mgd,5,mg/kg,TRUE,0.5,TRUE,75,mg/m2,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.6,
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan,None,10,10,2,Teozolomide Arm,FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Bevacizumab,10,mg/kg,TRUE,1,,,Temozolomide,50,mg/m2,FALSE,,TRUE,12.6,
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan,None,12,13,2,Etoposide Arm,FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Bevacizumab,10,mg/kg,TRUE,1,,,Etopside,50,mg/m2,FALSE,,TRUE,19,
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan,Death,1,13,2,Etoposide Arm,FALSE,FALSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Bevacizumab,10,mg/kg,TRUE,1,,,Etopside,50,mg/m2,FALSE,,TRUE,19,
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation,Withdrawal by Subject,3,42,2,Radiation Plus PPX(CT2103,TRUE,TRUE,,,,,,TRUE,PPX,50,mg/m2,TRUE,,TRUE,,,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,FALSE,,,,,,,,,,,,,TRUE,,
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation,None,39,42,2,Radiation Plus PPX(CT2103,TRUE,TRUE,,,,,,TRUE,PPX,50,mg/m2,TRUE,,TRUE,,,TRUE,TRUE,,,,,,,,,,,,,,,TRUE,FALSE,FALSE,,,,,,,,,,,,,TRUE,,
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation,Withdrawal by Subject,3,21,2,Radiation + Temozolomide,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,,,,,,,,,,,TRUE,FALSE,FALSE,,,,,,,,,,,,,FALSE,,
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation,None,18,21,2,Radiation + Temozolomide,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,,,,,,,,,,,TRUE,FALSE,FALSE,,,,,,,,,,,,,FALSE,,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Adverse Event,1,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Progressive Disease,17,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Lost to Follow-up,7,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Death,6,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Withdrawal by Subject,13,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Protocol Violation,1,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Not Specified,1,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),None,1,47,4,Temozolomide + Radiation,TRUE,TRUE,,,,,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,13.17,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Adverse Event,1,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Progressive Disease,23,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Lost to Follow-up,5,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Death,3,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Withdrawal by Subject,4,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Protocol Violation,3,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),Not Specified,3,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572),None,10,52,4,"Temozolomide Alone, Then Temozolomide + Radiation",TRUE,TRUE,TRUE,Temozolomide,75,mg/m2,TRUE,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,200,mg/m2,,,,,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,17.58,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Unsatisfactory therapeutic effect,25,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Adverse Event,18,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Withdrawal by Subject,14,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Death,5,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Study drug no longer required,5,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Lost to Follow-up,2,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Abnormal laboratory value(s),0,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Protocol Violation,0,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Suspected progression of disease,44,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,None,7,120,3,Imatinib Mesylate + Hydroxyurea (HU),FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Imatinib Mesylate,600,mg,FALSE,,,,Hydroxyurea,1000,mg,FALSE,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Unsatisfactory therapeutic effect,26,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Adverse Event,20,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Withdrawal by Subject,10,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Death,13,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Study drug no longer required,3,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Lost to Follow-up,1,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Abnormal laboratory value(s),2,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Protocol Violation,1,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,Suspected progression of disease,30,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,None,14,120,3,Hydroxyurea Alone,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,Hydroxyurea,1500,mg,FALSE,,,,,,,,,FALSE,,
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,None,309,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Protocol Violation,8,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Death,0,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Physician Decision,0,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Insufficient tissue,0,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Disease Progression,0,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Patient Refusal,0,317,3,Randomized Arm 1: TMZ+RT + Placebo,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Placebo,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,16.1,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,None,312,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Protocol Violation,8,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Death,0,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Physician Decision,0,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Insufficient tissue,0,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Disease Progression,0,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma,Patient Refusal,0,320,3,Randomized Arm 2: TMZ+RT + Bevacizumab,TRUE,TRUE,,,,,,TRUE,,,,,,TRUE,75,mg/m2,TRUE,TRUE,75,mg/m2,,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,TRUE,FALSE,,,,,,,,,,,,,,TRUE,15.7,TRUE
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,None,29,29,2,"Arm 1, HSPPC-96 + Concomitant Bevacizumab",FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,HSPPC-96,0.4,mL,FALSE,,TRUE,0.5,Bevacizumab,10,mg/kg,TRUE,1,TRUE,6.6,
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,None,30,30,2,"Arm 2, HSPPC-96 With Bevacizumab at Progression",FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,HSPPC-96,0.4,mL,FALSE,,TRUE,0.5,Bevacizumab,10,mg/kg,TRUE,1,TRUE,9.2,
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,None,31,31,2,"Arm 3, Bevacizumab",FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,Bevacizumab,10,mg/kg,TRUE,1,,,,,,,,TRUE,10.7,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,0,8,1,Phase I: Dose Level 1,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,20,mg,FALSE,,,,Temozolomide,60,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,8,8,1,Phase I: Dose Level 1,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,20,mg,FALSE,,,,Temozolomide,60,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,1,7,1,Phase I: Dose Level 2a,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,60,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,6,7,1,Phase I: Dose Level 2a,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,60,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,0,9,1,Phase I: Dose Level 2b,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,20,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,9,9,1,Phase I: Dose Level 2b,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,20,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,0,8,1,Phase I: Dose Level 3,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,8,8,1,Phase I: Dose Level 3,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,2,75,2,Phase II: Arm 1/BEV-NAIVE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,10.3,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,73,75,2,Phase II: Arm 1/BEV-NAIVE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,10.3,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,3,76,2,Phase II: Arm 2/BEV-NAIVE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,150,mg,FALSE,,FALSE,10.7,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,73,76,2,Phase II: Arm 2/BEV-NAIVE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,150,mg,FALSE,,FALSE,10.7,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,4,36,2,Phase II: Arm 1/BEV-FAILURE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,4.7,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,32,36,2,Phase II: Arm 1/BEV-FAILURE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,75,mg,FALSE,,FALSE,4.7,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,Protocol Violation,1,38,2,Phase II: Arm 2/BEV-FAILURE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,150,mg,FALSE,,FALSE,4.7,
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma,None,37,38,2,Phase II: Arm 2/BEV-FAILURE,FALSE,TRUE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,TRUE,,ABT-888,40,mg,FALSE,,,,Temozolomide,150,mg,FALSE,,FALSE,4.7,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Protocol Violation,0,12,1,"Phase I, Dose Level 0",TRUE,FALSE,,,,,,TRUE,Vorinostat,300,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,500,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Cancel prior to treatment,0,12,1,"Phase I, Dose Level 0",TRUE,FALSE,,,,,,TRUE,Vorinostat,300,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,500,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,12,12,1,"Phase I, Dose Level 0",TRUE,FALSE,,,,,,TRUE,Vorinostat,300,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,500,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Protocol Violation,0,3,1,"Phase I, Dose Level 1",TRUE,FALSE,,,,,,TRUE,Vorinostat,400,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,500,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Cancel prior to treatment,0,3,1,"Phase I, Dose Level 1",TRUE,FALSE,,,,,,TRUE,Vorinostat,400,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,500,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,3,3,1,"Phase I, Dose Level 1",TRUE,FALSE,,,,,,TRUE,Vorinostat,400,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,500,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Protocol Violation,1,110,2,Phase II,TRUE,FALSE,,,,,,TRUE,Vorinostat,300,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,400,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",Cancel prior to treatment,2,110,2,Phase II,TRUE,FALSE,,,,,,TRUE,Vorinostat,300,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,400,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",None,107,110,2,Phase II,TRUE,FALSE,,,,,,TRUE,Vorinostat,300,mg,FALSE,,TRUE,75,mg/m2,TRUE,TRUE,150,mg/m2,,,Vorinostat,400,mg,FALSE,,,,,,,TRUE,FALSE,,,,,,,,,,,,,,FALSE,,
